Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays

Cancer Cell

Volumn 31, Issue 2, 2017, Pages 225-239

  Li, Jun ^a   Zhao, Wei ^a   Akbani, Rehan ^a   Liu, Wenbin ^a   Ju, Zhenlin ^a   Ling, Shiyun ^a   Vellano, Christopher P ^a   Roebuck, Paul ^a   Yu, Qinghua ^a   Eterovic, A Karina ^a   Byers, Lauren A ^a   Davies, Michael A ^a   Deng, Wanleng ^a   Gopal, Y N Vashisht ^a   Chen, Guo ^a   von Euw, Erika M ^b   Slamon, Dennis ^b   Conklin, Dylan ^b   Heymach, John V ^a   Gazdar, Adi F ^c   Minna, John D ^c   Myers, Jeffrey N ^a   Lu, Yiling ^a   Mills, Gordon B ^a   Liang, Han ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

biomarker; cancer cell lines; data portal; drug sensitivity; proteomics; reverse phase protein array; signaling pathways

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PROTEIN P53; TRAMETINIB; TRANSCRIPTION FACTOR YAP1; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEARNING ALGORITHM; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVERSE PHASE PROTEIN ARRAY; WEB BROWSER; BIOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 85012908020     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.01.005     Document Type: Article

References (40)

1. Akbani, R., Ng, P.K., Werner, H.M., Shahmoradgoli, M., Zhang, F., Ju, Z., Liu, W., Yang, J.Y., Yoshihara, K., Li, J., et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun., 5, 2014, 3887.
2. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
3. Byers, L.A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P.K., et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19 (2013), 279–290.
4. Cancer Cell Line Encyclopedia Consortium, Genomics of Drug Sensitivity in Cancer Consortium, Pharmacogenomic agreement between two cancer cell line data sets. Nature 528 (2015), 84–87.
5. Cheung, L.W., Walkiewicz, K.W., Besong, T.M., Guo, H., Hawke, D.H., Arold, S.T., Mills, G.B., Regulation of the PI3K pathway through a p85alpha monomer-homodimer equilibrium. Elife, 4, 2015, e06866.
6. Daemen, A., Griffith, O.L., Heiser, L.M., Wang, N.J., Enache, O.M., Sanborn, Z., Pepin, F., Durinck, S., Korkola, J.E., Griffith, M., et al. Modeling precision treatment of breast cancer. Genome Biol., 14, 2013, R110.
7. Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367 (2012), 1694–1703.
8. Formisano, L., Nappi, L., Rosa, R., Marciano, R., D'Amato, C., D'Amato, V., Damiano, V., Raimondo, L., Iommelli, F., Scorziello, A., et al. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Res., 16, 2014, R45.
9. Gao, W., Wang, M., Wang, L., Lu, H., Wu, S., Dai, B., Ou, Z., Zhang, L., Heymach, J.V., Gold, K.A., et al. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J. Natl. Cancer Inst., 106, 2014, 10.1093/jnci/dju204.
10. Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483 (2012), 570–575.
11. Gygi, S.P., Rochon, Y., Franza, B.R., Aebersold, R., Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19 (1999), 1720–1730.
12. Haibe-Kains, B., El-Hachem, N., Birkbak, N.J., Jin, A.C., Beck, A.H., Aerts, H.J., Quackenbush, J., Inconsistency in large pharmacogenomic studies. Nature 504 (2013), 389–393.
13. Haura, E.B., Rix, U., Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. J. Natl. Cancer Inst., 106, 2014, 10.1093/jnci/dju250.
14. Hennessy, B.T., Lu, Y., Gonzalez-Angulo, A.M., Carey, M.S., Myhre, S., Ju, Z., Davies, M.A., Liu, W., Coombes, K., Meric-Bernstam, F., et al. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin. Proteomics 6 (2010), 129–151.
15. Hu, J., He, X., Baggerly, K.A., Coombes, K.R., Hennessy, B.T., Mills, G.B., Non-parametric quantification of protein lysate arrays. Bioinformatics 23 (2007), 1986–1994.
16. Ince, T.A., Sousa, A.D., Jones, M.A., Harrell, J.C., Agoston, E.S., Krohn, M., Selfors, L.M., Liu, W., Chen, K., Yong, M., et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat. Commun., 6, 2015, 7419.
17. Ju, Z., Liu, W., Roebuck, P.L., Siwak, D.R., Zhang, N., Lu, Y., Davies, M.A., Akbani, R., Weinstein, J.N., Mills, G.B., et al. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics 31 (2015), 912–918.
18. Klijn, C., Durinck, S., Stawiski, E.W., Haverty, P.M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33 (2015), 306–312.
19. Leiserson, M.D., Vandin, F., Wu, H.T., Dobson, J.R., Eldridge, J.V., Thomas, J.L., Papoutsaki, A., Kim, Y., Niu, B., McLellan, M., et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47 (2015), 106–114.
20. Li, J., Lu, Y., Akbani, R., Ju, Z., Roebuck, P.L., Liu, W., Yang, J.Y., Broom, B.M., Verhaak, R.G., Kane, D.W., et al. TCPA: a resource for cancer functional proteomics data. Nat. Methods 10 (2013), 1046–1047.
21. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008), 704–715.
22. Marcotte, R., Sayad, A., Brown, K.R., Sanchez-Garcia, F., Reimand, J., Haider, M., Virtanen, C., Bradner, J.E., Bader, G.D., Mills, G.B., et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164 (2016), 293–309.
23. Mertins, P., Mani, D.R., Ruggles, K.V., Gillette, M.A., Clauser, K.R., Wang, P., Wang, X., Qiao, J.W., Cao, S., Petralia, F., et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534 (2016), 55–62.
24. Moghaddas Gholami, A., Hahne, H., Wu, Z., Auer, F.J., Meng, C., Wilhelm, M., Kuster, B., Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4 (2013), 609–620.
25. Monti, S., Tamayo, P., Mesirov, J., Golub, T., Consensus clustering: a resampling- based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52 (2003), 91–118.
26. Nam, H.J., Im, S.A., Oh, D.Y., Elvin, P., Kim, H.P., Yoon, Y.K., Min, A., Song, S.H., Han, S.W., Kim, T.Y., et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol. Cancer Ther. 12 (2013), 16–26.
27. Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W.C., Waltham, M., Kouros-Mehr, H., Bussey, K.J., Lee, J.K., Espina, V., et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. USA 100 (2003), 14229–14234.
28. Seashore-Ludlow, B., Rees, M.G., Cheah, J.H., Cokol, M., Price, E.V., Coletti, M.E., Jones, V., Bodycombe, N.E., Soule, C.K., Gould, J., et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5 (2015), 1210–1223.
29. Sheehan, K.M., Calvert, V.S., Kay, E.W., Lu, Y., Fishman, D., Espina, V., Aquino, J., Speer, R., Araujo, R., Mills, G.B., et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell Proteomics 4 (2005), 346–355.
30. Singh, A., Settleman, J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29 (2010), 4741–4751.
31. Spurrier, B., Ramalingam, S., Nishizuka, S., Reverse-phase protein lysate microarrays for cell signaling analysis. Nat. Protoc. 3 (2008), 1796–1808.
32. Stelzl, U., Worm, U., Lalowski, M., Haenig, C., Brembeck, F.H., Goehler, H., Stroedicke, M., Zenkner, M., Schoenherr, A., Koeppen, S., et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122 (2005), 957–968.
33. Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K.P., et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43 (2015), D447–D452.
34. Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G.B., Kornblau, S.M., Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5 (2006), 2512–2521.
35. Tyanova, S., Albrechtsen, R., Kronqvist, P., Cox, J., Mann, M., Geiger, T., Proteomic maps of breast cancer subtypes. Nat. Commun., 7, 2016, 10259.
36. Wu, H., Wang, A., Zhang, W., Wang, B., Chen, C., Wang, W., Hu, C., Ye, Z., Zhao, Z., Wang, L., et al. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget 6 (2015), 31313–31322.
37. Yang, J.Y., Yoshihara, K., Tanaka, K., Hatae, M., Masuzaki, H., Itamochi, H., Cancer Genome Atlas Research, N., Takano, M., Ushijima, K., Tanyi, J.L., et al. Predicting time to ovarian carcinoma recurrence using protein markers. J. Clin. Invest. 123 (2013), 3740–3750.
38. Yang, J.Y., Werner, H.M., Li, J., Westin, S.N., Lu, Y., Halle, M.K., Trovik, J., Salvesen, H.B., Mills, G.B., Liang, H., Integrative protein-based prognostic model for early stage endometrioid endometrial cancer. Clin. Cancer Res. 22 (2015), 513–523.
39. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M.C., Zimmerman, L.J., Shaddox, K.F., Kim, S., et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513 (2014), 382–387.
40. Zhang, H., Liu, T., Zhang, Z., Payne, S.H., Zhang, B., McDermott, J.E., Zhou, J.Y., Petyuk, V.A., Chen, L., Ray, D., et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166 (2016), 755–765.